Holen Sie sich die Stockscreener-App
45.11
1.61%
-0.74
Handel nachbörslich:
45.11
Schlusskurs vom Vortag:
$45.85
Offen:
$45.6
24-Stunden-Volumen:
495.46K
Relative Volume:
0.59
Marktkapitalisierung:
$2.62B
Einnahmen:
$776.83M
Nettoeinkommen (Verlust:
$-29.02M
KGV:
-88.11
EPS:
-0.512
Netto-Cashflow:
$82.25M
1W Leistung:
-6.55%
1M Leistung:
-2.36%
6M Leistung:
-15.37%
1J Leistung:
+0.51%
1-Tages-Spanne:
$44.81
$45.86
1-Wochen-Bereich:
$44.81
$49.82
52-Wochen-Spanne:
$42.45
$59.68
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Firmenname
Supernus Pharmaceuticals Inc
Sektor
Telefon
301-838-2500
Adresse
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
45.11 | 2.76B | 776.83M | -29.02M | 82.25M | -0.512 |
TAK
Takeda Pharmaceutical Co Adr
|
18.24 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.16 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.93 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.17 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
512.88 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-09 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Fortgesetzt | Jefferies | Buy |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-04-13 | Hochstufung | Jefferies | Hold → Buy |
| 2020-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Fortgesetzt | Jefferies | Hold |
| 2019-11-08 | Herabstufung | Berenberg | Buy → Hold |
| 2019-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2019-11-06 | Herabstufung | Jefferies | Buy → Hold |
| 2018-11-12 | Bestätigt | B. Riley FBR | Buy |
| 2018-01-18 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-08 | Hochstufung | Stifel | Hold → Buy |
| 2017-10-19 | Eingeleitet | FBR & Co. | Buy |
| 2017-09-19 | Herabstufung | Stifel | Buy → Hold |
| 2017-07-17 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Eingeleitet | Janney | Neutral |
| 2017-06-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Hochstufung | Jefferies | Hold → Buy |
| 2015-11-05 | Bestätigt | Northland Capital | Outperform |
| 2015-10-28 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
A Look at Supernus Pharmaceuticals Inc (SUPN) After 3.4% Decline -- GF Value $43.78 vs Price $45.85 - GuruFocus
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - Yahoo Finance
25,400 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by Mystic Asset Management Inc. - MarketBeat
Indivior stock steadies after Supernus merger deal highlights $2.2 billion revenue goal - Ad-hoc-news.de
Supernus Pharmaceuticals (SUPN) Stock Looks Reasonable On Sales While Returns Look Strong - Sahm
Britannia, US WorldMeds, Supernus must face US Apokyn antitrust case, plaintiffs say - MLex
Supernus (SUPN) Results Review: The Available Earnings Metric Delivers a Beat in the Latest Reading; After Results: Shares Move 0.35% Lower in the Current UpdateGuidance Revision Trend - vinanet.vn
Supernus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SUPN) - TradingView
Indivior Q2 2026 Earnings Call: Complete Transcript - Sahm
Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Sahm
Rice Hall James & Associates LLC Takes $22.80 Million Position in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Supernus Pharmaceuticals, Inc. $SUPN Shares Purchased by Bank of America Corp DE - MarketBeat
Details of Bhatt’s PSU Vesting and Tax Withholding at Supernus Pharmaceuticals - Kalkine Media
Supernus Pharmaceuticals CMO Jonathan Rubin Reports Vesting of 750 PSUs and Share Withholding for Taxes - Kalkine Media
Supernus Pharmaceuticals (SUPN) CEO exercises PSUs, withholds shares for taxes - Stock Titan
Supernus Pharmaceuticals (SUPN) CMO Rubin exercises PSUs and withholds shares for tax - Stock Titan
Supernus Pharmaceuticals (SUPN) SVP converts 1,650 PSUs; 797 shares withheld for taxes - Stock Titan
Supernus Pharmaceuticals (SUPN) exec converts 2,500 PSUs, withholds shares for tax - Stock Titan
Supernus Pharmaceuticals, Inc.: Revenue and Earnings Analysts Forecasts Revisions | SUPN | US8684591089 - marketscreener.com
Morgan Lewis Advises Supernus Pharmaceuticals on Merger with Indivior Pharmaceuticals – News - Morgan Lewis
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Why (SUPN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts - Yahoo Finance
Indivior Pharmaceuticals (INDV) Agrees Merger That Creates New Supernus, Inc. - simplywall.st
Supernus Pharmaceuticals, Inc. (SUPN) Investor Outlook: A 31% Upside Potential Amid Strong Revenue Growth - DirectorsTalk Interviews
Supernus Pharmaceuticals (SUPN) Stock May Be A Bargain After Merger News - Yahoo Finance
Supernus Pharmaceuticals Inc. (S49.SG) Q2 FY2025 earnings call transcript - Yahoo Finance
Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
supernus pharmaceuticals, inc. Positive Earnings Pre-Announcements - RTTNews
Arrowstreet Capital Limited Partnership Trims Holdings in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Hold" at Wall Street Zen - MarketBeat
Supernus Pharmaceuticals, Inc. (SUPN) Indivior Pharmaceuticals, Inc.,M&A CallSlideshow - Seeking Alpha
Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders? - TradingView
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc.SUPN - marketscreener.com
New Strong Buy Stocks for August 7th - The Globe and Mail
Best Value Stocks to Buy for August 7th - The Globe and Mail
Millennium group (SUPN) reports Supernus stake falls below 5% ownership - Stock Titan
Rockville-Based Supernus and Indivior Agree to Merge, Creating a $2.2B CNS Powerhouse Headquartered in Maryland - BioBuzz
Rx Rundown: Supernus Pharmaceuticals, TCGX, Sandoz and more - Medical Marketing and Media
Q2 2026 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Supernus And Indivior To Merge And Create $2.2 Billion CNS Biopharmaceutical Company - Pulse 2.0
Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call High - GuruFocus
Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth ... - Yahoo! Finance Canada
Supernus Pharmaceuticals (NASDAQ:SUPN) Trading Down 6%Here's Why - MarketBeat
Supernus Pharmaceuticals Falls as Investors Weigh Newly Announced Indivior Merger Terms - moomoo.com
Supernus Pharmaceuticals falls as investors weigh newly announced Indivior merger terms - Quiver Quantitative
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Supernus and Indivior to Merge, Creating Diversified CNS Biopharma Company - Contract Pharma
$1.8bn merger unites Supernus and Indivior in CNS therapeutics play - BioXconomy
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook - Yahoo Finance
Supernus and Indivior merge to create scaled, CNS-focused entity - Yahoo Finance
Finanzdaten der Supernus Pharmaceuticals Inc-Aktie (SUPN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Supernus Pharmaceuticals Inc-Aktie (SUPN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Rubin Jonathan | SVP, Chief Medical Officer |
Aug 12 '26 |
Option Exercise |
0.00 |
750 |
0 |
14,342 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Aug 12 '26 |
Option Exercise |
0.00 |
2,500 |
0 |
19,795 |
| Mottola Frank | SVP, Chief Tech. Ops. Officer |
Aug 12 '26 |
Option Exercise |
0.00 |
1,650 |
0 |
20,341 |
| DEC TIMOTHY C | Senior Vice-President & CFO |
Aug 12 '26 |
Option Exercise |
0.00 |
1,250 |
0 |
9,733 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 17 '26 |
Option Exercise |
38.51 |
50,000 |
1,925,537 |
67,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Option Exercise |
33.62 |
50,000 |
1,681,205 |
67,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Option Exercise |
39.40 |
7,250 |
285,650 |
24,294 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 17 '26 |
Sale |
50.30 |
50,000 |
2,514,886 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Sale |
50.28 |
50,000 |
2,513,925 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Sale |
49.60 |
7,250 |
359,621 |
17,044 |
1.12%
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):